Ryo Shirahama Takamichi Ono Suguru Nagamatsu Daisuke Sueta Seiji Takashio Tadasuke Chitose Koichiro Fujisue Kenji Sakamoto Eiichiro Yamamoto Yasuhiro Izumiya Koichi Kaikita Seiji Hokimoto Mika Hori Mariko Harada-Shiba Ichiro Kajiwara Hisao Ogawa Kenichi Tsujita
10.2169/internalmedicine.1060-18
Intern Med
2018;57(24):3551-3557.
double-heterozygous familial hypercholesterolemia pcsk9 inhibitor plaque regression
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/30555118/
Antibodies, Monoclonal / therapeutic use Anticholesteremic Agents / therapeutic use Hyperlipoproteinemia Type II / drug therapy Hyperlipoproteinemia Type II / genetics Plaque, Amyloid / drug therapy Proprotein Convertase 9 / genetics Receptors, LDL / genetics Rosuvastatin Calcium / therapeutic use
Antibodies, Monoclonal / therapeutic use Anticholesteremic Agents / therapeutic use Hyperlipoproteinemia Type II / drug therapy Hyperlipoproteinemia Type II / genetics Plaque, Amyloid / drug therapy Proprotein Convertase 9 / genetics Receptors, LDL / genetics Rosuvastatin Calcium / therapeutic use Case Reports Acute Coronary Syndrome / blood Acute Coronary Syndrome / diagnosis Acute Coronary Syndrome / pathology Adult Antibodies, Monoclonal, Humanized Cholesterol, LDL / blood Drug Therapy, Combination Ezetimibe / therapeutic use Heterozygote Humans Hyperlipoproteinemia Type II / blood Hyperlipoproteinemia Type II / complications Male Mutation Proprotein Convertase 9 / immunology Receptors, LDL / blood Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Anticholesteremic Agents Cholesterol, LDL Receptors, LDL Rosuvastatin Calcium PCSK9 protein, human Proprotein Convertase 9 Ezetimibe evolocumab
PMC6355420
30555118
Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
2018